| Date | Title | | | Jun 11, 2013 | St. Jude Medical Announces FDA Approval of High-Voltage Devices with New Safety Features| Next-generation implantable defibrillators feature additional safety
features to address common lead complications
ST. PAUL, Minn.--(BUSINESS WIRE)--Jun. 11, 2013--
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company,
today announced U.S. Food and Drug Administration (FDA) approval of its
next-generation Ellipse™ and SJM Assura™ portfolio of implantable
cardioverter defibrillators (ICDs) and cardiac resynchronization therapy
def... |
|  | | Jun 07, 2013 | St. Jude Medical Signs Equity Investment and Option to Purchase Agreement with Spinal Modulation| Agreement provides St. Jude Medical immediate international distribution
rights for the Axium Neurostimulator System and a longer-term exclusive
option to acquire the company
ST. PAUL, Minn. & MENLO PARK, Calif.--(BUSINESS WIRE)--Jun. 7, 2013--
St. Jude Medical, Inc. (NYSE: STJ), a global medical device company, and
privately-held Spinal Modulation, Inc., today announced that they have
entered into a series of agreements under which St. Jude Medi... |
| | | Jun 04, 2013 | St. Jude Medical Initiates First US Clinical Study of the EnligHTN Renal Denervation System for Drug-Resistant High Blood Pressure| ST. PAUL, Minn.--(BUSINESS WIRE)--Jun. 4, 2013--
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company,
today announced U.S. Food and Drug Administration (FDA) approval to
begin the EnligHTN IV Renal Denervation Study, the first U.S. trial
using the EnligHTN™
Multi-Electrode Renal Denervation System to treat patients
with drug-resistant high blood pressure.
It is estimated that one
in three American adults has hypertens... |
| | | May 23, 2013 | One Year Data from St. Jude Medical Study Demonstrates Safe, Rapid and Sustained Blood Pressure Reduction with EnligHTN Renal Denervation Technology| ST. PAUL, Minn. & PARIS--(BUSINESS WIRE)--May. 23, 2013--
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company,
today announced that the company’s EnligHTN™
Multi-Electrode Renal Denervation System provides a safe, rapid and
sustained reduction in blood pressure measurements after one year. The
new one year study data from the EnligHTN I trial was presented today at
EuroPCR 2013 in Paris.
The EnligHTN(TM) Multi-Electrode ... |
| | | May 21, 2013 | St. Jude Medical EnligHTNment Study Highlighted at EuroPCR During Trials That May Change Clinical Practice Session| ST. PAUL, Minn. & PARIS--(BUSINESS WIRE)--May. 21, 2013--
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company,
today announced the start of its landmark EnligHTNment clinical study.
This is the largest randomized, prospective trial to determine whether
renal denervation and medication offers additional health benefits
beyond lowering blood pressure in patients with uncontrolled
hypertension. The EnligHTNment study will evaluate the Enl... |
| | | May 21, 2013 | St. Jude Medical to Present at the 38th Annual Deutsche Bank Health Care Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--May. 21, 2013--
St. Jude Medical, Inc. (NYSE:STJ) will present at the 38th Annual
Deutsche Bank Health Care Conference on Wednesday, May 29, in Boston.
John Heinmiller, executive vice president, will address the conference
at 10:00 a.m. EDT. The presentation will also be webcast live at www.sjm.com.
About St. Jude Medical
St. Jude Medical, Inc. develops medical technology and services that
focus on... |
| | | May 16, 2013 | St. Jude Medical Announces European Approval of 3-D Vessel Reconstruction Technology to Aid Physicians in Stent Placement| Next-generation system provides a real-time 360-degree panoramic view of
the arteries in 3-D
ST. PAUL, Minn.--(BUSINESS WIRE)--May. 16, 2013--
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company,
today announced CE Mark approval of its ILUMIEN™ OPTIS™
PCI Optimization System™, a new technology designed to
provide physicians with a comprehensive disease assessment tool for
treating patients with coronary artery disease (CAD). The... |
| | | May 14, 2013 | St. Jude Medical Announces First Patient Enrollment in EnligHTN III Renal Denervation Study of Next-Generation EnligHTN System| New system offers simultaneous ablations with an intuitive touch screen
generator, potentially enabling faster procedure times for the treatment
of hypertension
ST. PAUL, Minn.--(BUSINESS WIRE)--May. 14, 2013--
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company,
today announced enrollment of the first patient in the EnligHTN III
trial. This study will evaluate the safety and performance of the new
second-generation EnligHTN™ Re... |
| | | May 09, 2013 | St. Jude Medical Announces Results from Independent Analysis of Optim-Insulated Defibrillation Leads in Late-Breaking Clinical Trial Session at Heart Rhythm 2013| Population Health Research Institute analysis continues to demonstrate
strong safety and reliability of Optim-insulated leads
ST. PAUL, Minn.--(BUSINESS WIRE)--May. 9, 2013--
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company,
today announced the Population Health Research Institute (PHRI), an
academic health science research institute, has conducted a further
independent analysis of data received from ongoing prospective
regis... |
| | | May 08, 2013 | St. Jude Medical Announces CE Mark Approval of Next-Generation Ellipse and SJM Assura High Voltage Devices| Next-generation implantable defibrillators feature additional safety
features to elevate the standard of care
ST. PAUL, Minn.--(BUSINESS WIRE)--May. 8, 2013--
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company,
today announced CE Mark approval of its next-generation Ellipse™ and SJM
Assura™ portfolio of implantable cardioverter defibrillators (ICDs) and
cardiac resynchronization therapy defibrillators (CRT-Ds). The new
portfoli... |
| | | May 03, 2013 | St. Jude Medical to Present at the Bank of America Merrill Lynch 2013 Health Care Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--May. 3, 2013--
St. Jude Medical, Inc. (NYSE:STJ) will present at the Bank of America
Merrill Lynch 2013 Health Care Conference on Tuesday, May 14, in Las
Vegas. Dan Starks, Chairman, President and Chief Executive Officer, will
address the conference at 9:20 a.m. PDT. The presentation will also be
webcast live at www.sjm.com.
About St. Jude Medical
St. Jude Medical, Inc. develops medical technology ... |
| | | May 02, 2013 | St. Jude Medical Enrolls First Patient in Next-Generation Quadra Study| The MultiPoint Pacing study is designed to show improved effectiveness
for patients when pacing multiple locations of the heart
ST. PAUL, Minn.--(BUSINESS WIRE)--May. 2, 2013--
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company,
today announced first enrollment of its MultiPoint™ Pacing
clinical study to build upon its first- to-market Quadripolar Pacing
System. Patients will be implanted with the Quadra Assura MP™
cardiac resy... |
| | | May 01, 2013 | St. Jude Medical Announces Second Quarter Dividend| Board declares second quarter dividend of $0.25 per share
ST. PAUL, Minn.--(BUSINESS WIRE)--May. 1, 2013--
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company,
today announced that its Board of Directors declared a second quarter
dividend of $0.25 per common share. This dividend amount is equal to the
dividend paid during the first quarter of 2013 and brings the total
dividend declared for the year to $0.50 per share. The dividend is
... |
| | | Apr 30, 2013 | St. Jude Medical Announces CE Mark and Launch of First Quadripolar CRT Pacemaker| Allure Quadra elevates the standard for Cardiac Resynchronization
Therapy Pacemakers
ST. PAUL, Minn.--(BUSINESS WIRE)--Apr. 30, 2013--
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company,
today announced CE Mark approval and European launch of its Allure Quadra™
Cardiac Resynchronization Therapy Pacemaker (CRT-P). This CRT-P system
offers more pacing options to deliver higher
success rates, as evidenced by robust clinical data. ... |
| | | Apr 17, 2013 | St. Jude Medical Reports First Quarter 2013 Results| ST. PAUL, Minn.--(BUSINESS WIRE)--Apr. 17, 2013--
St. Jude Medical, Inc. (NYSE: STJ) today reported sales and net earnings
for the first quarter ended March 30, 2013.
First Quarter Sales
The Company reported net sales of $1.338 billion in the first quarter of
2013, a decline of approximately 4 percent compared with the $1.395
billion in the first quarter of 2012. Unfavorable foreign currency
translation comparisons decreased first ... |
| | | Apr 10, 2013 | St. Jude Medical First to Receive CE Mark Approval of Deep Brain Stimulation Systems for Both Primary and Secondary Dystonia| Therapy offers new hope for patients suffering from disabling symptoms
of dystonia
ST. PAUL, Minn.--(BUSINESS WIRE)--Apr. 10, 2013--
St. Jude Medical, Inc. (NYSE: STJ), a global medical device company,
today announced European CE Mark approval of its Brio™, Libra™
and LibraXP™ deep brain stimulation (DBS) systems for
managing the symptoms of intractable primary and secondary dystonia,
a neurological movement disorder that causes a person’s mus... |
| | | Apr 04, 2013 | St. Jude Medical Announces First Quarter 2013 Earnings Conference Call| ST. PAUL, Minn.--(BUSINESS WIRE)--Apr. 4, 2013--
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, will
hold its quarterly conference call to discuss first quarter 2013 results
on Wednesday, April 17, 2013, at 8 a.m. EDT (7 a.m. CDT).
This call is being webcast by Thomson Reuters and can be accessed at St.
Jude Medical’s Investor Relations website
(www.sjm.com/corporate/investor-relations.aspx).
The webcast is als... |
| | | Mar 21, 2013 | St. Jude Medical Announces Public Offering of Senior Notes| ST. PAUL, Minn.--(BUSINESS WIRE)--Mar. 21, 2013--
St. Jude Medical, Inc. (NYSE:STJ) today announced that it has priced an
offering to sell $900 million of senior notes due 2023 (the "2023
Notes") and $700 million of senior notes due 2043 (the "2043 Notes").
The 2023 Notes will bear interest at 3.25% per year and, unless
previously redeemed, will mature on April 15, 2023. The 2043 Notes will
bear interest at 4.75% per year and, unless previously redee... |
| | | Mar 20, 2013 | Results of St. Jude Medical's RESPECT Trial Published in The New England Journal of Medicine|
Eight-year study confirms PFO closure was superior to medical therapy
alone in reducing risk of recurrent stroke in prespecified per-protocol
and as-treated cohorts
ST. PAUL, Minn.--(BUSINESS WIRE)--Mar. 20, 2013--
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company,
today announced publication of results from its landmark RESPECT trial in
The New England Journal of Medicine. The study results show that
device closure us... |
| | | Mar 19, 2013 | Newly Published Data Indicates St. Jude Medical Trifecta Heart Valve Closely Resembles the Hemodynamic Performance of a Natural, Healthy Heart Valve|
Study in The Journal of Thoracic and Cardiovascular Surgery
highlights the Trifecta valve’s excellent hemodynamic performance and
ease of implant
ST. PAUL, Minn.--(BUSINESS WIRE)--Mar. 19, 2013--
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company,
announced that its Trifecta™
biological pericardial aortic valve has demonstrated positive results in
a new study published
online in The Journal of Thoracic and Cardio... |
| | | Mar 11, 2013 | St. Jude Medical Announces Launch of 3-D Vessel Reconstruction Technology in Japan|
Japan is the first market to offer the next-generation FFR and OCT
ILUMIEN OPTIS System for stent placement
ST. PAUL, Minn.--(BUSINESS WIRE)--Mar. 11, 2013--
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company,
today announced the launch of its ILUMIEN™ OPTIS™
System, a next-generation technology designed to help physicians make
personalized stenting decisions based on each patient’s unique anatomy
and disease state. The... |
| | | Mar 08, 2013 | St. Jude Medical Announces First Implant in Pivotal Phase of Clinical Trial Evaluating AMPLATZER Cardiac Plug for the Prevention of Stroke in Patients with Atrial Fibrillation| ST. PAUL, Minn.--(BUSINESS WIRE)--Mar. 8, 2013--
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company,
today announced the first patient implant in a new pivotal trial
evaluating the company’s AMPLATZER™
Cardiac Plug (ACP) for the prevention of stroke. The AMPLATZER™
Cardiac Plug Clinical Trial (ACP Trial) is designed to determine if the
ACP device is safe and effective in preventing thrombus (blood clots)
from migrating out of t... |
| | | Feb 27, 2013 | St. Jude Medical to Present at the Barclays Global Healthcare Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--Feb. 27, 2013--
St. Jude Medical, Inc. (NYSE:STJ) will present at the Barclays Global
Healthcare Conference on Tuesday, March 12, in Miami. John Heinmiller,
executive vice president, will address the conference at 10:15 a.m. EDT.
The presentation will also be webcast live at www.sjm.com.
About St. Jude Medical
St. Jude Medical, Inc. develops medical technology and services that
focus on putting... |
| | | Feb 25, 2013 | St. Jude Medical Announces Increase in Quarterly Dividend|
Board of Directors declares 9 percent increase in quarterly dividend
ST. PAUL, Minn.--(BUSINESS WIRE)--Feb. 25, 2013--
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company,
today announced that its Board of Directors declared a nine percent
increase in the company’s quarterly dividend to $0.25 per common share.
At the new rate, the annual dividend would be $1.00 per share, compared
to the previous annual dividend of $0.92 per sh... |
| | | Feb 15, 2013 | St. Jude Medical Initiates Landmark Study of Renal Denervation for Reduction of Heart Attack, Stroke and Death|
EnligHTNment trial will evaluate whether patients with hypertension that
are treated with renal denervation and medication experience additional
benefits beyond a reduction in blood pressure
ST. PAUL, Minn.--(BUSINESS WIRE)--Feb. 15, 2013--
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company,
today announced plans for a new landmark study that will evaluate
whether renal denervation and medication can provide health benefits to... |
| | | Feb 08, 2013 | Data from St. Jude Medical RESPECT Trial for PFO Closure Highlighted at International Stroke Conference 2013|
Presentation of neurological data confirms patients in the device group
had fewer, smaller strokes that were less likely to originate from blood
clots passing through the PFO
ST. PAUL, Minn.--(BUSINESS WIRE)--Feb. 8, 2013--
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company,
today announced the presentation of additional data from its landmark
RESPECT trial at the American Stroke Association’s International Stroke
Confe... |
| | | Feb 04, 2013 | St. Jude Medical Announces First Implant Evaluating New Size of Portico Heart Valve in Ongoing European Clinical Trial| ST. PAUL, Minn.--(BUSINESS WIRE)--Feb. 4, 2013--
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company,
today announced the first patient implant of its 25 mm Portico™
Transcatheter Aortic Heart Valve using the Transfemoral Delivery
System in its ongoing European trial. The Portico valve system offers a
minimally invasive treatment option for patients with severe aortic
stenosis – a narrowing of the aortic valve that obstructs blood flow... |
| | | Jan 30, 2013 | St. Jude Medical Announces First Patient Enrollment in EnligHTN II Renal Denervation Study|
Company expands evaluation of its EnligHTN renal denervation technology
for hypertension to new patient populations
ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 30, 2013--
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company,
today announced enrollment of the first patient in the EnligHTN II
trial. This post-market clinical study will further evaluate the safety
and efficacy of the EnligHTN™
Renal Denervation System in patients... |
| | | Jan 28, 2013 | St. Jude Medical Announces 2013 Annual Investor Meeting| ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 28, 2013--
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, will
hold its 2013 Annual Investor Meeting on Friday, Feb. 1, 2013, from 8:00
a.m. – 12:30 p.m. Eastern time (7 a.m. Central time).
This call is being webcast by Thomson Reuters and can be accessed at St.
Jude Medical’s Investor Relations website
(www.sjm.com/corporate/investor-relations.aspx).
The webcast is al... |
| | | Jan 23, 2013 | St. Jude Medical Reports Fourth Quarter and Full-Year 2012 Results| ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 23, 2013--
St. Jude Medical, Inc. (NYSE: STJ) today reported sales and net earnings
for the fourth quarter and year ended December 29, 2012.
Fourth Quarter and Full-Year Sales
The Company reported net sales of $1.372 billion in the fourth quarter
of 2012, a decline of approximately 2 percent compared with the $1.407
billion in the fourth quarter of 2011. Unfavorable foreign currency
transl... |
| | | Jan 18, 2013 | St. Jude Medical Receives CE Mark of Next-Generation Cardiac Device for Stroke Prevention|
AMPLATZER Amulet unveiled at 18th annual Boston AF Symposium
ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 18, 2013--
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company,
today announced European CE Mark approval of its AMPLATZER™
Amulet™ Left Atrial Appendage Occluder. The Amulet device is
used to close the left atrial appendage (LAA) in patients diagnosed with
non-valvular atrial fibrillation (AF). According to research, AF leads
... |
| | | Jan 17, 2013 | St. Jude Medical Announces CE Mark Approval of ViewFlex Xtra ICE Catheter|
New catheter provides real-time, high-resolution ultrasound images of
blood flow and cardiac anatomy when paired with the ViewMate Z
Intracardiac Ultrasound Console
ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 17, 2013--
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company,
today announced European CE Mark approval of its ViewFlex™
Xtra Intracardiac Echocardiography (ICE) Catheter. Designed for
control and maneuverability durin... |
| | | Jan 16, 2013 | St. Jude Medical Announces FDA Approval of New Version of Remote Patient Monitoring System|
Next-Generation Merlin.net Patient Care Network (PCN) represents
important advancement in the management of patients with heart failure
ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 16, 2013--
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company,
today announced U.S. Food and Drug Administration (FDA) approval of the
next-generation Merlin.net™ Patient Care Network (PCN), a
secure, Internet-based remote care system for patients with im... |
| | | Jan 09, 2013 | St. Jude Medical Announces Preliminary Fourth Quarter Financial Results| ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 9, 2013--
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company,
today announced preliminary revenue results for the fourth quarter ended
Dec. 29, 2012. These results will be referenced today in a presentation
by the Chairman, President and Chief Executive Officer of St. Jude
Medical, Daniel J. Starks, at the 31st Annual J.P. Morgan
Healthcare Conference in San Francisco. A webcast of the presentati... |
| | | Jan 07, 2013 | St. Jude Medical Announces Fourth Quarter and Full Year 2012 Earnings Conference Call| ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 7, 2013--
St. Jude Medical, Inc. (NYSE: STJ), a global medical device company,
will hold its quarterly conference call to discuss fourth quarter and
full year 2012 results on Wednesday, Jan. 23, 2013, at 8 a.m. EST (7
a.m. CST).
This call is being webcast by Thomson Reuters and can be accessed at St.
Jude Medical’s Investor Relations website
(www.sjm.com/corporate/investor-relations.aspx).
... |
| |
|
